Jee-Young Han1,2, Lilah M Besser3, Chengjie Xiong1,2, Walter A Kukull4, John C Morris1,2. 1. Knight Alzheimer Disease Research Center. 2. Washington University in St. Louis School of Medicine, St. Louis, MO. 3. School of Urban and Regional Planning and Institute for Healthy Aging and Lifespan Studies, Florida Atlantic University, Boca Raton, FL. 4. National Alzheimer's Coordinating Center, University of Washington, Seattle, WA.
Abstract
INTRODUCTION: We investigated whether cholinesterase inhibitors (ChEIs) benefit cognitive outcomes in mild cognitive impairment due to Alzheimer disease (MCI-AD) and in mild AD dementia (ADdem). METHODS: Data from 2242 individuals, clinically diagnosed with MCI-AD [Clinical Dementia Rating (CDR), 0 or 0.5] or with mild ADdem (CDR, 0.5 or 1), were available from the National Alzheimer's Coordinating Center's (NACC) Uniform Data Set (UDS). General linear mixed models were used to examine the annual change in the CDR Sum of Boxes (CDR-SB) and in neuropsychological performance. We compared slopes before and after ChEI initiation among ChEI users, and also compared the change in scores of ChEI users versus nonusers. RESULTS: Thirty-four percent of 944 MCI-AD and 72% of 1298 ADdem participants were ChEI users. Cognitive decline was greater after ChEI initiation in MCI-AD and ADdem groups (eg, MCI-AD, CDR-SB: 0.03 points/y before initiation; 0.61 points/y after initiation, P<0.0001). Both MCI-AD and ADdem groups had faster decline after ChEI initiation than nonusers (eg, MCI-AD, CDR-SB: 0.61 points/y, ChEI users; 0.24 points/y, nonusers, P<0.0001). DISCUSSION: This study suggests that ChEI use may not improve the cognitive course in MCI-AD and mild ADdem.
INTRODUCTION: We investigated whether cholinesterase inhibitors (ChEIs) benefit cognitive outcomes in mild cognitive impairment due to Alzheimer disease (MCI-AD) and in mild AD dementia (ADdem). METHODS: Data from 2242 individuals, clinically diagnosed with MCI-AD [Clinical Dementia Rating (CDR), 0 or 0.5] or with mild ADdem (CDR, 0.5 or 1), were available from the National Alzheimer's Coordinating Center's (NACC) Uniform Data Set (UDS). General linear mixed models were used to examine the annual change in the CDR Sum of Boxes (CDR-SB) and in neuropsychological performance. We compared slopes before and after ChEI initiation among ChEI users, and also compared the change in scores of ChEI users versus nonusers. RESULTS: Thirty-four percent of 944 MCI-AD and 72% of 1298 ADdem participants were ChEI users. Cognitive decline was greater after ChEI initiation in MCI-AD and ADdem groups (eg, MCI-AD, CDR-SB: 0.03 points/y before initiation; 0.61 points/y after initiation, P<0.0001). Both MCI-AD and ADdem groups had faster decline after ChEI initiation than nonusers (eg, MCI-AD, CDR-SB: 0.61 points/y, ChEI users; 0.24 points/y, nonusers, P<0.0001). DISCUSSION: This study suggests that ChEI use may not improve the cognitive course in MCI-AD and mild ADdem.
Authors: J C Morris; S Edland; C Clark; D Galasko; E Koss; R Mohs; G van Belle; G Fillenbaum; A Heyman Journal: Neurology Date: 1993-12 Impact factor: 9.910
Authors: Ronald C Petersen; Ronald G Thomas; Michael Grundman; David Bennett; Rachelle Doody; Steven Ferris; Douglas Galasko; Shelia Jin; Jeffrey Kaye; Allan Levey; Eric Pfeiffer; Mary Sano; Christopher H van Dyck; Leon J Thal Journal: N Engl J Med Date: 2005-04-13 Impact factor: 91.245
Authors: Duane L Beekly; Erin M Ramos; William W Lee; Woodrow D Deitrich; Mary E Jacka; Joylee Wu; Janene L Hubbard; Thomas D Koepsell; John C Morris; Walter A Kukull Journal: Alzheimer Dis Assoc Disord Date: 2007 Jul-Sep Impact factor: 2.703
Authors: Celina S Liu; Nathan Herrmann; Bing Xin Song; Joycelyn Ba; Damien Gallagher; Paul I Oh; Susan Marzolini; Tarek K Rajji; Jocelyn Charles; Purti Papneja; Mark J Rapoport; Ana C Andreazza; Danielle Vieira; Alex Kiss; Krista L Lanctôt Journal: BMC Geriatr Date: 2021-12-04 Impact factor: 3.921